Paul Tudor Jones Zentalis Pharmaceuticals, Inc. Transaction History
Tudor Investment Corp Et Al
- $44 Billion
- Q2 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 34,849 shares of ZNTL stock, worth $51,925. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,849
Previous 34,849
-0.0%
Holding current value
$51,925
Previous $55,000
27.27%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ZNTL
# of Institutions
122Shares Held
60.6MCall Options Held
0Put Options Held
22K-
Matrix Capital Management Company, LP Waltham, MA14MShares$20.8 Million8.42% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$7.18 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.48MShares$5.18 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$4.3 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.8MShares$4.17 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $84.9M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...